logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
logotype
logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us

Tag: Counterfeit

Blog Image 1-01
July 31, 2025
by info@virtueinsight.comNews

Torrent Pharmaceuticals to acquire stake in JB Pharma for $3bn

Torrent Pharmaceuticals, has signed definitive agreements for the acquisition of a controlling stake in JB Chemicals and Pharmaceuticals (JB Pharma) from global investment firm KKR at an equity valuation of Rs256.89bn ($3bn) on a fully diluted basis. The move is part of...
read more
Merck logo-01
July 31, 2025
by info@virtueinsight.comNews

Merck & Co. To Acquire Verona Pharma for $10 Bn

Merck has agreed to acquire biopharmaceutical company Verona Pharma in a deal valued at $10bn. The acquisition will be made by the subsidiary of Merck, which is known as MSD outside of the US and Canada. The deal values London-based Verona at about $107 per American depository share,...
read more
Untitled
July 31, 2025
by info@virtueinsight.comNews

Sanofi completes acquisition of Blueprint Medicines

Sanofi announced the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and the expertise of a company specializing in systemic mastocytosis (SM), a rare immunological disease, and...
read more
Blog Image-01
June 20, 2025
by info@virtueinsight.comNews

BioNTech to Acquire CureVac for $1.25 Billion

BioNTech announced a $1.25 billion all-stock acquisition of CureVac through a public exchange offer, offering $5.46 per CureVac share representing a 55% premium to strengthen its mRNA-based cancer immunotherapy capabilities. The strategic transaction will combine complementary mRNA...
read more
lilly logo-01
June 20, 2025
by info@virtueinsight.comNews

Eli Lilly acquires SiteOne Therapeutics

Eli Lilly and Company and SiteOne Therapeutics, , a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, announced a definitive agreement for Lilly to acquire SiteOne “The global...
read more
Untitled
June 17, 2025
by info@virtueinsight.comNews

Sanofi buys Vigil Neuroscience for $470m in Alzheimer’s push

Sanofi has agreed to acquire Vigil Neuroscience in a $470m deal, nearly a year after investing an initial $40m in the company. The deal will see Sanofi acquire all outstanding common shares of US-based Vigil for $8 per share in cash at closing. Although Vigil has two candidates in...
read more
images
December 26, 2024
by info@virtueinsight.comNews

Novo Holdings completes Catalent acquisition for $16.5bn

Novo Holdings, a global investment firm focused on life sciences, has completed its previously announced acquisition of Catalent. Under private ownership, Catalent benefits from Novo Holdings’ significant resources, and is well-positioned to deliver unparalleled outcomes for...
read more
abbvie
December 26, 2024
by info@virtueinsight.comNews

AbbVie buys Nimble Therapeutics for $200M

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. As part of the acquisition, the North Chicago-based Big Pharma will also dole out undisclosed interim payments. Shareholders of the...
read more
ge
December 26, 2024
by info@virtueinsight.comNews

GE HealthCare fully acquires Japanese pharma company

GE HealthCare has acquired full ownership of a leading radiopharmaceutical firm Nihon Medi-Physics, that generated $183 million in revenue last year.  NMP’s product portfolio includes GE HealthCare radiopharmaceuticals delivered across neurology, cardiology and oncology. Among them...
read more
December 26, 2024
by info@virtueinsight.comNews

AbbVie to Acquire Aliada Therapeutics

AbbVie and Aliada Therapeutics had announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases....
read more
  • 1
  • 2
  • 3
  • …
  • 6
logotype

We strive to produce high quality conferences which include the latest topics which are delivered by world class leaders of the industry.

Facebook-fTwitterYoutubeLinkedin-inInstagramPinterest

Quick Links

About us
Contact us
Event Support
Careers
Privacy Policy
Terms & Conditions

Subscribe to our newsletter

    © 2025 Virtue Insight. All rights reserved.